摘要
目的探讨重组人血管内皮抑素联合放疗治疗非小细胞肺癌的临床效果。方法回顾性分析2010年2月间至2013年2月110例非小细胞肺癌患者资料,分为观察组和对照组(每组55例)。对照组患者采用放疗治疗,观察组患者加用重组人血管内皮抑素,比较两组患者的临床效果。结果观察组患者CR、PR、SD、PD的百分比分别为3.6%、47.3%、14.5%和34.6%,客观有效率(RR)为50.9%,疾病控制率(DCR)为65.5%。对照组患者CR、PR、SD、PD的百分比分别为1.8%、27.3%、25.5%和45.5%,RR为29.09%,DCR为54.6%。对照组患者生活质量改善率、稳定率及下降率分别为21.8%、30.9%及47.3%,观察组患者分别为52.7%、23.6%和23.6%。两组患者白细胞减少、血小板减少、恶心呕吐、肝肾功能损害、外周神经损害、心脏毒性、心电图改变比较,差异有统计学意义(P<0.05)。结论重组人血管内皮抑素联合放疗治疗非小细胞肺癌临床效果显著。
Objective To investigate the clinical effect of recombinant human endostatincombined with radiotherapy for non-small cell lung cancer. Methods A retrospective analysis of 110 patients with non-small cell lung cancer hospitalized from February 2010 to February 2013 were made and the patients were divided into the observation group and the control group （55 cases respectively）. The control group re- ceived the radiotherapy treatment, and the observation group added recombinant human endostatin treat- ment. Clinical effects were compared between the two groups after treatment. Results The clinical CR, PR, SD, PD rates of observation group were 3.6%, 47. 3 %, 14. 5 %, 34. 6% respectively, RR 50. 9%, and DCR 65.5%. Those of the control group were 1.8% ,27. 3% ,25.5% and 45.5% respectively,RR 29. 1% , and DCR 54. 6%. From quality of life situation, the improvement, stable and decrease rates of the control group were 21.8% ,30. 9% and 47.3% respectively and those of observation group were 52. 7% ,23.6% and 23. 6% respectively. There were significant differences among the adverse reactions such as leukopenia, thrombocytopenia, nausea and vomiting, liver and kidney damage, peripheral nerve damage, cardiac toxicity between the two groups （ P 〈0. 05 ）. Conclusion Clinical effect of recombinant human endostatin com- bined with radiotherapy for non small cell lung cancer was significant.
出处
《中国肿瘤临床与康复》
2014年第7期814-816,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
重组人血管内皮抑素
放射治疗
癌
非小细胞肺
治疗结果
Endothelial recombinant human endostatin
Radiotherapy
Carcinoma, non-smallcell lung
Treatment outcome
